Arexvy has been approved by the Health Sciences Authority (HSA) of Singapo...
DEERFIELD, Ill., May 16, 2024 /PRNewswire/ -- Baxter International Inc. (NYSE:BAX), a global medtech...
SYDNEY, May 16, 2024 /PRNewswire/ -- Manhattan Associates Inc. (NASDAQ: MANH), a global leader in su...
JOHOR BAHRU, Malaysia, May 16, 2024 /PRNewswire/ -- Panduit, a global leader and manufacturer of cut...
SINGAPORE, May 16, 2024 /PRNewswire/ -- HIX.AI, an all-in-one AI writing copilot has officially laun...
BEIJING, May 16, 2024 /PRNewswire/ -- A news report from China.org.cn on why did the Chinese accept...
SUZHOU, China and ROCKVILLE, Md., May 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global ...
TAIPEI, May 16, 2024 /PRNewswire/ -- In Taiwan, sisters Yu-Qi Wu and Yu-Hsuan Wu have transformed a ...
British company's fuel cell is a commercially-viable, turnkey solution U...
British company's fuel cell is a commercially-viable, turnkey solution U...
ภาษาไทย
English![CISION PR Newswire - HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]](https://mma.prnasia.com/media2/2412228/GSK_Asia_House_Singapore.jpg?p=medium600)
